Please login to the form below

Not currently logged in
Email:
Password:

etoricoxib

This page shows the latest etoricoxib news and features for those working in and with pharma, biotech and healthcare.

Grunenthal to market MSD’s pain drug

Grunenthal to market MSD’s pain drug

Acquires rights to Arcoxia in several European countries. Grünenthal has agreed a deal with MSD to market its pain medicine Arcoxia (etoricoxib) in several major European markets. ... In these countries, Grünenthal will hold exclusive promotion and

Latest news

  • EMEA counsels COX-2 action

    With regard to other COX-2 inhibitor pain relievers available within the EU, which include celecoxib (Celebrex; Pfizer), etoricoxib (Arcoxia; Merck &Co), and parecoxib (Dynastat; Pharmacia), the EMEA affirmed that the

  • Merck lambasted over semi-revelation

    The trial, which spread itself across 38 countries, saw Arcoxia (etoricoxib) pitted head to head against diclofenac, an older non-steroidal anti-inflammatory drug (NSAID) already widely prescribed in arthritis communities.

  • RA market to flourish

    Meanwhile, approval of Merck's Arcoxia (etoricoxib) for RA has been delayed in the US pending further safety and efficacy data, although it is already launched in the UK and several

  • News in brief, May 02, 2007

    Regulatory news. FDA rejects Vioxx replacement. The FDA has rejected Merck &Co's request to market Arcoxia (etoricoxib), a replacement for its withdrawn arthritis drug, Vioxx (rofecoxib). ... Wolfe noted that trial data presented by Merck on

  • News in brief, April 11, 2007

    The announcement will not please US pharmaceutical company, Merck &Co, which is waiting for an FDA ruling on its Vioxx (rofecoxib) replacement, Arcoxia (etoricoxib).

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health is an integrated communications agency designed for and inspired by the ever-changing face of healthcare. In London, we...

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...

Infographics